Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 5/20 | 0.52 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 3/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30151697 | 1.00 | F2R (0.52) | F2RDGAT2KIF11S1PR3TACR1 | |
| SCHEMBL30636560 | 1.00 | F2R (0.52) | F2RDGAT2KIF11S1PR3TACR1 | |
| SCHEMBL23932346 | 0.90 | F2R (0.54) | F2RDGAT2KIF11TACR1MGLL | |
| SCHEMBL30151696 | 0.83 | F2R (0.53) | F2RDGAT2KIF11TACR1MGLL | |
| SCHEMBL23960644 | 0.83 | F2R (0.53) | F2RDGAT2KIF11TACR1MGLL | |
| SCHEMBL30151669 | 0.79 | BRD4 (0.41) | ROCK2 | |
| SCHEMBL26078682 | 0.79 | BRD4 (0.41) | ROCK2 | |
| SCHEMBL23960534 | 0.72 | F2R (0.43) | F2R | |
| SCHEMBL23960590 | 0.72 | F2R (0.43) | F2R | |
| SCHEMBL23932436 | 0.72 | F2R (0.43) | F2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310445-A1 | LOX ENZYME INHIBITING METHODS AND COMPOSITIONS | ANOVIA BIOSCIENCES, INC. | 2023-10-05 | — | — | US | disclosed |
| US-20230310445-A1 | LOX ENZYME INHIBITING METHODS AND COMPOSITIONS | ANOVIA BIOSCIENCES, INC. | 2023-10-05 | — | — | US | disclosed |
| WO-2021216592-A1 | LOX ENZYME INHIBITING METHODS AND COMPOSITIONS | ANOVIA BIOSCIENCES, INC. (US) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310445-A1 | LOX ENZYME INHIBITING METHODS AND COMPOSITIONS | LOX, LOXL1, LOXL2 | F2R 300/4885DGAT2 572/4885KIF11 4736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.